CLERMONT-FERRAND, France--(BUSINESS WIRE)--Regulatory News:
CARBIOS (Paris:ALCRB) (Euronext Growth Paris: ALCRB), pioneer company in the field of bioplasturgy, is pleased to announce that it has been selected by EuropaBio as one of the top two finalists that will compete for the Most Innovative EU Biotech SME Award 2017 in the Industrial Biotech category.
This Awards program represents a unique annual initiative (now in its eighth year) that recognizes innovative biotech small- and medium-sized enterprises (SMEs) in Europe and the key role that they play in addressing some of the greatest challenges of our society.
As a shortlisted company for this year’s edition, CARBIOS will attend the Awards ceremony hosted in the European Parliament in Brussels by MEP and Jury member, Dr. Paul RUEBIG on November 22nd. The event will be attended by high-level representatives of the European biotech industry, EU policymakers, venture capitalists and other leaders in the biotech community.
“It’s an honour to have been shortlisted for this Award. Our pioneering approach based on the use of enzymes will bring cutting-edge solutions to the way we handle the life-cycle of plastics. This recognition shows how scientific breakthroughs based on circular economy principles can be applied to address today’s industrial and environmental challenges” said Jean-Claude LUMARET, Chief Executive Officer of CARBIOS.
About CARBIOS
CARBIOS is a green chemistry company whose innovations are designed to meet environmental and sustainable development issues faced by global industrial players. Since its creation in 2011, CARBIOS has developed two industrial bioprocesses dedicated to the biodegradation and the biorecycling of polymers. These breakthrough innovations, which are a worldwide premiere, leverage the highly specific properties of enzymes to optimize the performances and the life cycle of plastic and textile materials. CARBIOS’ economic development model is based on the industrialization and commercialization of its products, enzymes, technologies, and bioprocesses via the concession of licenses, directly or via joint ventures to major industrial players in the sectors that can make use of the Company’s innovative technologies. For instance, CARBIOS created in September 2016, the joint-venture CARBIOLICE, in partnership with Limagrain Céréales Ingrédients and the SPI investment fund run by Bpifrance. This company, controlled by CARBIOS, will operate the first patented enzymatic biodegradation technology licensed by CARBIOS by producing enzymated pellets to be used for the production of a new generation of bio-sourced and biodegradable plastics. Since inception, CARBIOS benefits from the financial support of the leading European venture capital firm Truffle Capital. CARBIOS was granted the label “Young Innovative Company” by Bpifrance (former OSEO) and is eligible for investments by private equity mutual funds (FCPIs).
CARBIOS is eligible for the PEA-PME, a government program allowing French residents investing in SMEs to benefit from income tax rebates.
For more information, please visit: www.carbios.fr
About EuropaBio’s European Biotech SME Awards 2017
EuropaBio, the European Association for Bioindustries, invited SMEs across Europe to apply for the 8th edition of the Most Innovative European Biotech SME Award. Depending on their field of activity, SMEs could apply in 3 categories: healthcare, agricultural or industrial biotech. Two companies were shortlisted in each category by a jury or biotech experts, with the winners celebrated during a landmark event for SMEs held in late November. The members of EuropaBio are involved in research, development, testing, manufacturing and commercialization of biotech products and processes in human and animal healthcare, diagnostics, bioinformatics, chemicals, crop protection, agriculture, food and environmental products and services. EuropaBio also counts a number of National Biotech Associations in its membership who in turn represent more than 1800 biotech SMEs. EuropaBio’s SME Platform focuses its activities on highlighting challenges and financial constraints that biotech SMEs face, and developing policy recommendations to optimise EU and member state funding instruments for biotech SMEs. The SME Platform brings together CEOs of SMEs, National Biotech Associations, Venture Capitalists and private banks, European financial institutions, representatives from the EC, and other interested stakeholders.
